Cephalon

Teva’s Cephalon acquisition could be delayed

pharmafile | June 15, 2011 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Cephalon, Teva 

The Federal Trade Commission has requested more information about Teva’s deal with Cephalon, potentially delaying the purchase by a month.

The US economic and business regulator sent requests for additional information to the generics giant Teva and the US-based Cephalon over their $6.8 billion deal in May.

It’s the second such request from the FTC and, after both companies have filed the requested information, the regulator will then extend its deadline for deciding on the deal by a maximum of 30 days.

On top of this extra delay, Teva also needs clearance by the European Commission under the EC Merger Regulation, as well as the approval of Cephalon stockholders.

Advertisement

Despite this however, the Israeli firm is still confident that the deal will be given the go-ahead by the third quarter.

Ben Adams

Related Content

Teva announces positive results from trial of AJOVY for migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

judge-gavel-1461966002dbr

Teva’s cancer drug Bendeka protected from generics until 2031, judge rules

A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe …

The Gateway to Local Adoption Series

Latest content